Business Wire

Swiss Virtual Clinic uniquely designed for Cataract Surgery

20.3.2025 17:07:00 CET | Business Wire | Press Release

Share

If you or someone you know is dealing with cataract surgery, sorting through the sheer volume of information can be overwhelming. Reliable details aren’t always easy to find, which is exactly why the Swiss Virtual Clinic was created by Swiss Advanced Vision (SAV-IOL SA). This first-of-its-kind online platform offers tailored access for both patients and eyecare professionals, making it simpler than ever to access the right information in one place.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320758061/en/

Cataract surgery is one of the most common eye procedures, yet for many patients, it still feels like a mystery. The Swiss Virtual Clinic makes things clearer with an easy-to-use interface that explains the procedure, potential concerns, and what to expect - all for free on sav-iol.com.

For eyecare professionals, keeping up with the latest in cataract surgery can be a challenge. From available tools to technical queries, finding information takes time - time that could be better spent focusing on patients. The newly launched Swiss Virtual Clinic offers a dedicated section, packed with valuable resources to support their work. And the best part? It’s designed to be intuitive and regularly updated so professionals can find exactly what they need when they need it. Since this pro section contains specialized medical content, users will need to register to ensure that only experts in the field can engage with the materials.

This launch is a major evolution and reinforces SAV-IOL’s portfolio built on innovation, quality, and precision. “And it marks just the beginning. More features are already in the pipeline as we continue adapting to the evolving needs of ophthalmic surgeons and their patients,” says Alexandre Pascarella, CEO of Swiss Advanced Vision.

If you’re an eyecare professional looking to save time and streamline your practice, now’s the perfect moment to join the Swiss Virtual Clinic. Subscriptions are open on sav-iol.com! For those attending the APAO Congress this year, there’s an opportunity to experience exclusive insights firsthand. From 3rd to 6th April, Swiss Advanced Vision will be showcasing the latest innovation at its booth in New Delhi.

Since 2009, SAV-IOL develops and markets advanced EDOF IOLs globally. Its LUCIDIS and EDEN lenses, powered by Instant Focus technology, provide continuous vision from near to intermediate and far distances.

The Swiss Virtual Clinic opens the door to brand new tailored services accompanying surgeons and their medical teams as well as patients to approach cataract surgery in a truly disruptive way.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250320758061/en/

Contacts

Hülya AYDIN
Brand & Marketing Manager
hulya.aydin@sav-iol.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press Release

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press Release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press Release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press Release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press Release

Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end workflows spanning onboarding, KYC, AML, fraud, underwriting, payments, disputes, servicing, and collections. For

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye